MX2021006696A - Derivado de cicloalcano-1,3-diamina. - Google Patents

Derivado de cicloalcano-1,3-diamina.

Info

Publication number
MX2021006696A
MX2021006696A MX2021006696A MX2021006696A MX2021006696A MX 2021006696 A MX2021006696 A MX 2021006696A MX 2021006696 A MX2021006696 A MX 2021006696A MX 2021006696 A MX2021006696 A MX 2021006696A MX 2021006696 A MX2021006696 A MX 2021006696A
Authority
MX
Mexico
Prior art keywords
mll
leukemia
menin
fusion protein
gene
Prior art date
Application number
MX2021006696A
Other languages
English (en)
Inventor
Kenji Yoshikawa
Yoshiko Kagoshima
Noriyasu Haginoya
Tomoaki Hamada
Jun Watanabe
Taeko Shinozaki
Ryutaro Kanada
Eri Tokumaru
Kenji Murata
Takayuki Baba
Mayumi Kitagawa
Akiko Kurimoto
Masashi Numata
Machiko Shiroishi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2021006696A publication Critical patent/MX2021006696A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención proporciona un compuesto o una sal farmacéuticamente aceptable del mismo que tiene una acción inhibidora de la interacción entre menina y una proteína MLL; el compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable del mismo; (ver Fórmula) Fórmula 1 en donde, en la fórmula (1), el circulo punteado, R1, R2, R3, R4, R5, R6, R7, R8, el anillo Q1, W, m y n son cada uno como se define en la descripción.
MX2021006696A 2018-12-06 2019-12-05 Derivado de cicloalcano-1,3-diamina. MX2021006696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018229397 2018-12-06
PCT/JP2019/048834 WO2020116662A1 (ja) 2018-12-06 2019-12-05 シクロアルカン−１，３−ジアミン誘導体

Publications (1)

Publication Number Publication Date
MX2021006696A true MX2021006696A (es) 2021-07-07

Family

ID=70974277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006696A MX2021006696A (es) 2018-12-06 2019-12-05 Derivado de cicloalcano-1,3-diamina.

Country Status (16)

Country Link
US (3) US20230030720A1 (es)
EP (1) EP3892278B1 (es)
JP (1) JP7417540B2 (es)
KR (1) KR20210100612A (es)
CN (1) CN113164481A (es)
AU (1) AU2019395201A1 (es)
BR (1) BR112021007421A2 (es)
CA (1) CA3116141C (es)
CO (1) CO2021008253A2 (es)
IL (1) IL282905A (es)
MX (1) MX2021006696A (es)
PH (1) PH12021550869A1 (es)
SG (1) SG11202104243VA (es)
TW (1) TW202039512A (es)
WO (1) WO2020116662A1 (es)
ZA (1) ZA202102876B (es)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255528B2 (en) 2002-07-10 2009-07-16 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
SE0301654D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
JP2007507551A (ja) 2003-10-03 2007-03-29 ポートラ ファーマシューティカルズ， インコーポレイテッド ２，４−ジオキソ−３−キナゾリニルアリールスルホニル尿素
AU2005240942B2 (en) 2004-05-10 2010-08-05 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
EP2007707A1 (en) 2006-04-07 2008-12-31 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
ES2662332T3 (es) 2010-03-04 2018-04-06 Merck Sharp & Dohme Corp. Inhibidores de la catecol-O-metil-transferasa y su uso en el tratamiento de trastornos psicóticos
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
BR112014001665A2 (pt) 2011-07-27 2017-02-14 Glaxo Group Ltd compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
LT2794600T (lt) 2011-12-22 2018-02-26 Novartis Ag 2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito
WO2014049133A1 (en) 2012-09-28 2014-04-03 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
JP2016500073A (ja) 2012-11-19 2016-01-07 ノバルティス アーゲー 寄生虫病の処置のための化合物および組成物
CN104903331A (zh) 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
CA2904612A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
SG11201608242XA (en) * 2014-04-04 2016-10-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6673850B2 (ja) 2014-04-14 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ヘテロアリール置換されたヘテロシクリルスルホン
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
SG11201807834WA (en) * 2016-03-16 2018-10-30 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
JP6919977B2 (ja) 2016-03-16 2021-08-18 クラ オンコロジー，インク． メニン−ｍｌｌの置換された阻害剤及びその使用方法
SI3468966T1 (sl) 2016-06-10 2021-03-31 Vitae Pharmaceuticals, Llc Zaviralci interakcije menin-MLL
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
TWI757340B (zh) 2016-09-16 2022-03-11 美商生命醫藥有限責任公司 梅嫩蛋白（ｍｅｎｉｎ）-ＭＬＬ相互作用之抑制劑
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction

Also Published As

Publication number Publication date
US20230074669A1 (en) 2023-03-09
CO2021008253A2 (es) 2021-07-19
US20210269454A1 (en) 2021-09-02
SG11202104243VA (en) 2021-05-28
PH12021550869A1 (en) 2021-10-18
IL282905A (en) 2021-06-30
US11236106B2 (en) 2022-02-01
WO2020116662A1 (ja) 2020-06-11
JPWO2020116662A1 (ja) 2021-10-21
BR112021007421A2 (pt) 2021-08-03
EP3892278A1 (en) 2021-10-13
JP7417540B2 (ja) 2024-01-18
CN113164481A (zh) 2021-07-23
KR20210100612A (ko) 2021-08-17
CA3116141C (en) 2023-09-05
EP3892278A4 (en) 2022-08-24
EP3892278B1 (en) 2024-02-28
ZA202102876B (en) 2022-10-26
CA3116141A1 (en) 2020-06-11
TW202039512A (zh) 2020-11-01
AU2019395201A1 (en) 2021-05-20
US20230030720A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
Tarumoto et al. LKB1, salt-inducible kinases, and MEF2C are linked dependencies in acute myeloid leukemia
Scharer et al. Global DNA methylation remodeling accompanies CD8 T cell effector function
Tee et al. Chromatin features and the epigenetic regulation of pluripotency states in ESCs
Fowle et al. PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
Schwartz et al. A new world of Polycombs: unexpected partnerships and emerging functions
Relogio et al. Ras-mediated deregulation of the circadian clock in cancer
Vázquez-Arreguín et al. The Oct1 transcription factor and epithelial malignancies: Old protein learns new tricks
Shinde et al. Phosphoproteomics reveals that glycogen synthase kinase-3 phosphorylates multiple splicing factors and is associated with alternative splicing
Mao et al. Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma
You et al. SNF5 is an essential executor of epigenetic regulation during differentiation
Chari et al. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death
Cao et al. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency
Xu et al. CTCF controls HOXA cluster silencing and mediates PRC2-repressive higher-order chromatin structure in NT2/D1 cells
Markouli et al. Structure, activity and function of the SETDB1 protein methyltransferase
Kiselev et al. Perturbations of PIP3 signalling trigger a global remodelling of mRNA landscape and reveal a transcriptional feedback loop
Liu et al. A functional role for the histone demethylase UTX in normal and malignant hematopoietic cells
US20170313978A1 (en) Endogenous retrovirus transcription as a marker for primate naive pluripotent stem cells
Cartularo et al. Molecular mechanisms of malignant transformation by low dose cadmium in normal human bronchial epithelial cells
Kirtana et al. Molecular mechanisms of KDM5A in cellular functions: Facets during development and disease
Kim et al. The WTX tumor suppressor interacts with the transcriptional corepressor TRIM28
Haley et al. Altered transcriptional control networks with trans-differentiation of isogenic mutant-KRas NSCLC models
Basile et al. Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations
Akpa et al. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
Markey Regulation of MDM4
Imesch et al. MLH1-deficient HCT116 colon tumor cells exhibit resistance to the cytostatic and cytotoxic effect of the poly (A) polymerase inhibitor cordycepin (3'-deoxyadenosine) in vitro